4D Pharma to collaborate with MSD in vaccine development

pharmafile | October 8, 2019 | News story | Manufacturing and Production  

4D pharma, a leader in the development of live biotherapeutics, has announced it has entered into a research collaboration to discover and develop live biotherapeutics for vaccines.

Under the terms of the agreement 4D’s proprietary MicroRx platform will be paired with MSD’s expertise in the development and commercialisation of novel vaccines to develop LBPs as vaccines in up to three undisclosed indications.

4D also retains the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration.

Additionally, as well as an upfront cash payment 4D will be eligible to receive up to $347.5 million in option exercise and deve3lopment and regulatory milestone payments.

MSD will be solely responsible for the development, manufacturing and commercialisation following the exercise of any of its exclusive options.

Duncan Peyton, Chief Executive Officer at 4D, commented: “This research collaboration agreement brings together 4D’s innovation in the microbiome space and MSD’s track record of developing cutting-edge vaccines.

“MSD and 4D have worked closely combining world leading science to develop a workplan to advance the understanding of this field with the aim of generating a new class of vaccines in areas of high unmet need.”

Daria Hazuda, MSD’s Vice President of Infectious Diseases and Vaccines Discovery Research, added: “A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health.

“By applying 4D’s MicroRx technology we hope to gain meaningful insights into the role for the hose microbiome in modulating the immune response and ultimately protection conferred by vaccines.”

Nik Kiran

Related Content

No items found

Latest content